Results 121 to 130 of about 32,878 (253)

Koebner phenomenon in a patient with hypertrophic chronic cutaneous lupus erythematosus. [PDF]

Postepy Dermatol Alergol, 2021
Dobrzyńska M, Polańska A, Bowszyc-Dmochowska M, Jenerowicz D, Lisowski S, Czarnecka-Operacz M, Adamski Z, Dańczak-Pazdrowska A.   +7 more
europepmc   +1 more source

Effect of Belimumab on the Cutaneous Manifestations of Patients With Lupus Erythematosus

International Journal of Dermatology, EarlyView.
ABSTRACT Background The aim was to assess the long‐term effect of belimumab on the cutaneous manifestations of patients with systemic lupus erythematosus (SLE). Methods The retrospective analysis included 29 patients with SLE. Cutaneous disease activity was assessed using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the
Diana Schellin, Sarah Rösing, Nick Zimmermann, Nicolai Leuchten, Martin Aringer, Claudia Günther   +5 more
wiley   +1 more source

Current Insights Into The Management Of Discoid Lupus Erythematosus

Clinical, Cosmetic and Investigational Dermatology, 2019
Jaime Company-Quiroga,* Sergio Alique-García,* Alberto Romero-MatéDermatology Department, Fuenlabrada Univesity Hospital, Madrid, Spain*These authors contributed equally to this workCorrespondence: Jaime Company-QuirogaDermatology ...
Company-Quiroga J, Alique-García S, Romero-Maté A   +2 more
doaj  

Drug-induced subacute cutaneous lupus erythematosus secondary to Dupilumab: A case report

SAGE Open Medical Case Reports
We present the case of a 63-year-old male with known rheumatoid arthritis, diabetes, hypertension, and peripheral neuropathy who developed drug-induced subacute cutaneous lupus erythematosus secondary to Dupilumab for his chronic hand dermatitis.
Miranda Waugh, Geneviève Gavigan
doaj   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus. [PDF]

Ann Rheum Dis, 2021
Jenks SA, Wei C, Bugrovsky R, Hill A, Wang X, Rossi FM, Cashman K, Woodruff MC, Aspey LD, Lim SS, Bao G, Drenkard C, Sanz I.   +12 more
europepmc   +1 more source

Inflammatory niches as spatial drivers of disease mechanisms and targets for personalized treatment

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study provides a comprehensive review of how spatial transcriptomics reveals disease‐specific inflammatory niches across multiple skin disorders, highlighting key immune–stromal, neuro–immune and metabolic interactions that were previously unappreciated in non‐spatial analyses. Abstract Disease states are increasingly recognized as being shaped by
Rundong Jiang, Zhiqin Fang, Lam C. Tsoi, Johann E. Gudjonsson   +3 more
wiley   +1 more source

Dermatology 2.0: Precision medicine for inflammatory skin diseases

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Digital immune mapping of transcriptomics profiles from inflammatory skin disease biopsies enables precise molecular diagnosis, quantification of immune modules and personalized therapy selection by matching dominant immune signatures to targeted treatments.
Jeremy Di Domizio, Antoine Girardin, Curdin Conrad, Teofila Seremet, Michel Gilliet   +4 more
wiley   +1 more source

Significant improvement of refractory cutaneous lesions of lupus erythematosus with the use of anifrolumab: a report of two cases

Revista da Sociedade Portuguesa de Dermatologia e Venereologia
Anifrolumab, a monoclonal antibody targeting the interferon-1 receptor, is currently approved for the treatment of moderate- to-severe systemic lupus erythematosus, but emerging evidence highlights its potential efficacy in cases with predominant ...
Gilberto P. da Rosa, Isabel Antunes, Bárbara V. Granja, Patrícia Gomes, Rúben Costa, Filomena Azevedo, Alberto Mota   +6 more
doaj  

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth, Joseph F. Merola, Richard Furie, Kenneth Kalunian, Ronald F. van Vollenhoven, Juanita Romero‐Diaz, Qianyun Li, Weihong Yang, Catherine Barbey   +8 more
wiley   +1 more source